Impact of COVID-19 on pediatric pulmonology healthcare practice.
Halime Nayir BuyuksahinNagehan EmiralioğluDilber Ademhan TuralBeste ÖzsezenBirce SunmanIsmail GüzelkaşEbru Elmas YalcinDeniz Dogru ErsozHayriye Uğur ÖzçelikEmine Nural KiperPublished in: Pediatric pulmonology (2021)
In 2020, compared with 2019, outpatient visits decreased by 42.2%; from 8324 patients to 4804 patients and other laboratory procedures decreased after the pandemic started; PFTs including spirometry by 87.2%; from 2990 to 380 tests, diffusion capacity assessment from 172 to 55 tests, plethysmography from 172 to 53 and LCI from 70 to 9 tests, also high-speed video microscopy analyses by 64.3% from 300 to 107 patients, and gastric aspirate sampling by 75.5% from 42 to 9 patients. FFB procedures also decreased by 59.1%, from 142 to 58 patients, and only 15 were after the first reported case of COVID-19 in our country, and they were all for urgent indications. None of these patients was positive pretesting for COVID-19 who underwent the FFB. There was no significant decrease in patients' hospitalization due to pulmonary exacerbation in cystic fibrosis, interstitial lung disease, and primary ciliary dyskinesia.
Keyphrases
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- cystic fibrosis
- peritoneal dialysis
- coronavirus disease
- sars cov
- primary care
- high speed
- interstitial lung disease
- patient reported outcomes
- patient reported
- single cell
- mass spectrometry
- single molecule
- health insurance
- idiopathic pulmonary fibrosis
- respiratory syndrome coronavirus